logo-loader
viewGilead Sciences, Inc.

Gilead Sciences, Roche to study remdesivir/Actemra combination in coronavirus patients

Gilead’s remdesivir is currently approved as emergency treatment for coronavirus while Roche has been studying the effectiveness of arthritis treatment Actemra

Gilead Sciences, Inc. - Gilead Sciences, Roche to study remdesivir/Actemra combination in Covid-19 patients

Gilead Sciences Inc (NASDAQ:GILD) and Roche are to assess the combination of their drugs remdesivir and Actemra in severe coronavirus (COVID-19) cases.

The two pharma giants will recruit 450 patients globally and begin a phase III trial in June.

READ: Gilead Sciences' remdesivir to be available for selected Covid-19 patients in the UK

Gilead’s remdesivir, an investigational antiviral, is currently approved as emergency treatment for coronavirus in several countries after three trials confirmed it allows for a faster recovery.

Roche has also been studying the effectiveness of arthritis treatment Actemra in coronavirus patients, with results expected in the summer.

“Based on our current understanding, we believe that combining an antiviral with an immune modulator could potentially be an effective approach to treating patients with severe disease,” said Levi Garraway, Roche’s chief medical officer and head of global product development.

Shares in Gilead dipped 1% to US$74.29 in premarket trading.

Quick facts: Gilead Sciences, Inc.

Price: 76.76 USD

NASDAQ:GILD
Market: NASDAQ
Market Cap: $96.29 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

finnCap CEO Sam Smith says new year has begun 'phenomenally well' with...

finnCap Group PLC (LON:FCAP) CEO Sam Smith tells Proactive London's Andrew Scott they've recorded its best-ever quarter to June 2020 with revenues 50% higher than the same period last year. She says the three months saw them helping clients raise significant equity to strengthen balance sheets...

1 hour, 25 minutes ago

2 min read